Lab Pays $4M to Settle Doctor-Kickback Claims
By Bianca Bruno,
Courthouse News Service
| 12. 30. 2015
Untitled DocumentA San Diego-based medical diagnostics laboratory paid over $4 million to settle claims it gave kickbacks to physicians who referred patients to the company for genetic testing.
Pathway Genomics Corporation paid $4,036,622.74 in a civil settlement of claims it paid doctors in exchange for patient referrals for their genetic testing kits that analyze the risks for certain genetic cancers and diseases and test the responsiveness of certain medications. The tests are performed using a saliva sample that is typically collected by a patient's doctor and mailed to Pathway's lab for testing.
Federal investigators found Pathway violated the False Claims Act by offering physicians and medical groups reimbursements of up to $20 for each saliva kit they submitted for genetic testing. Individual physicians cashed in as much as $13,534 in kickbacks from Pathway and most had not ordered the costly genetic tests prior to enrolling in the reimbursement program, according to U.S. Attorney Laura Duffy.
Prosecutors also claimed Pathway billed federal health care programs such as Medicare and TRICARE to foot the cost of the testing.
Pathway has since...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...